OCEANSIDE,
CA--(InvestorsHub NewsWire
- May 22, 2017) - Therapeutics Solutions International,
Inc., (OTC PINK: TSOI) announced today the filing of a patent
covering a repurposing of the FDA cleared drug Mifepristone for use
in expansion of T and NK cells in cancer patients undergoing
immunotherapy.
The patent describes methods useful for improving a treatment
outcome and/or an alteration of immunity in a condition that
benefits from immune stimulation. In particular, the invention
teaches administration of sufficient doses of Mifepristone or a
derivative, alone, or in combination with an immunotherapeutic such
as an antibody, a vaccine, a cytokine, or a medicament whose
therapeutic activity is associated with immune
modulation.
LymphoBoost is a proprietary formulation of Mifepristone, a drug
approved for another indication, which we have shown to be capable
of stimulating lymphocytes, particularly NK cells and T cells, both
critical in maintaining anti-tumor immunity.
"Current cancer therapies are often associated with various
degrees of toxicity. One of the Company's core principles is to
develop approaches that are unlikely to cause toxicity by focusing
on naturally occurring products or repurposing of drugs that are
already demonstrated to be safe," said Timothy Dixon, President and
CEO of Therapeutic Solutions International. "Mifepristone has been
used in the USA since the year 2000 for its anti-progesterone
properties and its safety and pharmacology are well
characterized."
"The immune system does not work in isolation of other
physiological systems of the body," said Dr. Thomas Ichim, Director
of Therapeutic Solutions International. "Various types of tumors
have been shown to generate Progesterone Induced Blocking
Factor1,2,3 which
suppresses the immune cells whose role it is to kill the
tumor4,5.
By blocking progesterone activity with Mifepristone, our data
suggests the possibility of overcoming some aspects of cancer
induced immune suppression."
1 Gutiérrez-Rodríguez
et al. Proliferative and Invasive Effects of
Progesterone-Induced Blocking Factor in Human Glioblastoma
Cells. Biomed Res
Int. 2017;2017:1295087. https://www.ncbi.nlm.nih.gov/pubmed/28168193
2 Marquina-Sánchez
et al. The interplay between intracellular
progesterone receptor and PKC plays a key role in migration and
invasion of human glioblastoma cells. J Steroid
Biochem Mol Biol. 2016 Oct 4. pii:
S0960-0760(16)30261-8. https://www.ncbi.nlm.nih.gov/pubmed/27717886
3 Kyurkchiev
et al. Cells isolated from human glioblastoma
multiforme express progesterone-induced blocking factor
(PIBF). Cell Mol Neurobiol. 2014
May;34(4):479-89. https://www.ncbi.nlm.nih.gov/pubmed/24474429
4 Par
et al. Progesterone regulates IL12 expression in
pregnancy lymphocytes by inhibiting phospholipase A2.
Am J Reprod Immunol. 2003
Jan;49(1):1-5. https://www.ncbi.nlm.nih.gov/pubmed/12733588
5 Faust
et al. Progesterone-induced blocking factor inhibits
degranulation of natural killer cells.
Am J Reprod Immunol. 1999
Aug;42(2):71-5. https://www.ncbi.nlm.nih.gov/pubmed/10476687
About Therapeutic Solutions International,
Inc.
The Company's corporate website is www.therapeuticsolutionsint.com. Our new
products can be viewed on www.projuvenol.com and products can be
ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United
States Food and Drug Administration. These products are not
intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made.